Overall, our study findings provide compelling evidence of TRIM37’s pivotal role in driving RCC cell malignancy and chemotherapy resistance through orchestrating SMARCC2 expression and modulating the Wnt signaling pathway (Fig. 9). This evidence concerns the gene SMARCC2 and renal cell carcinoma.